Deltanoid Pharmaceuticals Announces Appointment of Douglas Jermasek as Chief Executive Officer

MADISON, WI, February 1, 2016, /PRNewswire/ — Deltanoid Pharmaceuticals, Inc. today announced the appointment of former Genzyme/Sanofi renal head, Douglas Jermasek as its new Chief Executive Officer. Mr. Jermasek replaces Deltanoid co-founder Hector F DeLuca, PhD, MD, DSC who will continue as Chairman of the Board of Directors and assume the responsibilities of Chief Operating Officer.

“Now over a decade since the founding of Deltanoid, I’m extremely proud of what our small team has accomplished in transitioning from a drug discovery into a clinical stage company with 3 promising compounds,” said Dr. DeLuca. “As we now progress our lead program, DP001 for the treatment of secondary hyperparathyroidism (SHPT) to phase 3 clinical development and ultimately commercialization, I am thrilled to be turning over the reins to Doug, who brings a 20 year track record of biopharmaceutical industry success and proven leadership in the renal space.”

“I’m very excited by the opportunity to lead Deltanoid as we complete the late-stage clinical development of DP001 and begin to shape the commercial opportunity for this uniquely differentiated product and its emerging best-in-class profile,” said Mr. Jermasek. “Among my first priorities will be to secure the capital investment needed to fund this exciting next stage of Deltanoid’s evolution as a company.”

Mr. Jermasek has over 20 years of biopharmaceutical industry experience. In his past role as Senior Vice President & General Manager of Genzyme/Sanofi’s global renal business, he drove sales over $ billion, establishing Renvela® as the standard of care for the treatment of hyperphosphatemia for patients with chronic kidney disease (CKD) and achieving “blockbuster” status globally. Outside of his 12 years at Genzyme/Sanofi Renal, Mr. Jermasek has held positions of progressive responsibility at Hybritech/Lilly, Abbott Laboratories, Agouron/Pfizer, Prometheus, and most recently as Head of North America at Intercept. Mr. Jermasek received an M.B.A. from the Marriott School of Management and a B.S. in biological science from Brigham Young University.

About Deltanoid Pharmaceuticals, Inc.

Founded out of the famed biochemistry lab of Hector F. DeLuca at the University of Wisconsin—Madison, Deltanoid Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company with a vision focused on unlocking the power of the vitamin D receptor (VDR) to transform the health outcomes of patients with diseases of the kidney, bone, and skin. For more information about Deltanoid, please visit